136 related articles for article (PubMed ID: 35927939)
21. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.
Celotto S; Veronese N; Barbagallo M; Ometto F; Smith L; Pardhan S; Barnett Y; Ilie PC; Soysal P; Lagolio E; Kurotschka PK; Tonelli R; Demurtas J
Int J Infect Dis; 2021 Feb; 103():599-606. PubMed ID: 33316389
[TBL] [Abstract][Full Text] [Related]
22. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Tsang AC; Ahmadi Pirshahid S; Virgili G; Gottlieb CC; Hamilton J; Coupland SG
Ophthalmology; 2015 Jun; 122(6):1239-1251.e4. PubMed ID: 25824328
[TBL] [Abstract][Full Text] [Related]
23. Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
Cui X; Sun J; Minkove SJ; Li Y; Cooper D; Couse Z; Eichacker PQ; Torabi-Parizi P
Rev Med Virol; 2021 Nov; 31(6):e2228. PubMed ID: 33694220
[TBL] [Abstract][Full Text] [Related]
24. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Cohen IV; Makunts T; Moumedjian T; Issa MA; Abagyan R
Sci Rep; 2020 Nov; 10(1):19199. PubMed ID: 33154498
[TBL] [Abstract][Full Text] [Related]
25. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Nicolò M; Ferro Desideri L; Bassetti M; Traverso CE
Int Ophthalmol; 2021 Feb; 41(2):719-725. PubMed ID: 32946004
[TBL] [Abstract][Full Text] [Related]
26. The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.
Biguetti CC; Junior JFS; Fiedler MW; Marrelli MT; Brotto M
Sci Rep; 2021 Mar; 11(1):6589. PubMed ID: 33758324
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Liu Y; Fu X; Xie C
Medicine (Baltimore); 2020 Sep; 99(37):e22031. PubMed ID: 32925737
[TBL] [Abstract][Full Text] [Related]
28. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
29. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
Chen Z; Liu A; Cheng Y; Wang X; Xu X; Huang J; Ma Y; Gao M; Huang C
BMC Infect Dis; 2021 Aug; 21(1):805. PubMed ID: 34384388
[TBL] [Abstract][Full Text] [Related]
30. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Gagnon LR; Sadasivan C; Yogasundaram H; Oudit GY
Curr Heart Fail Rep; 2022 Dec; 19(6):458-466. PubMed ID: 36167917
[TBL] [Abstract][Full Text] [Related]
31. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
Fatima U; Rizvi SSA; Fatima S; Hassan MI
J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593
[TBL] [Abstract][Full Text] [Related]
32. Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy.
Reichel C; Berlin A; Radun V; Tarau IS; Hillenkamp J; Kleefeldt N; Sloan KR; Ach T
Transl Vis Sci Technol; 2020 Aug; 9(9):42. PubMed ID: 32934892
[TBL] [Abstract][Full Text] [Related]
33. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?
Nessaibia I; Siciliano D; Tahraoui A
Int J Health Plann Manage; 2020 Nov; 35(6):1311-1313. PubMed ID: 32914465
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis.
Chivese T; Musa OAH; Hindy G; Al-Wattary N; Badran S; Soliman N; Aboughalia ATM; Matizanadzo JT; Emara MM; Thalib L; Doi SAR
Travel Med Infect Dis; 2021; 43():102135. PubMed ID: 34265436
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
Choi MY; Weber B; Stevens E; Guan H; Ellrodt J; Oakes E; Di Carli M; Tedrow U; Sauer W; Costenbader KH
Rheumatol Int; 2022 Oct; 42(10):1767-1774. PubMed ID: 35430712
[TBL] [Abstract][Full Text] [Related]
36. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
37. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
38. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
Doyno C; Sobieraj DM; Baker WL
Clin Toxicol (Phila); 2021 Jan; 59(1):12-23. PubMed ID: 32960100
[TBL] [Abstract][Full Text] [Related]
39. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Osadchy A; Ratnapalan T; Koren G
J Rheumatol; 2011 Dec; 38(12):2504-8. PubMed ID: 22002012
[TBL] [Abstract][Full Text] [Related]
40. Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
Yaylali SA; Sadigov F; Erbil H; Ekinci A; Akcakaya AA
Int Ophthalmol; 2013 Dec; 33(6):627-34. PubMed ID: 23456514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
